Precision Medicine Quarterly

Foundation Medicine Announces Global Collaboration With Lilly

2022-02-10T17:29:24-05:00February 10th, 2022|

Foundation Medicine, Inc. today announced a collaboration with Eli Lilly and Company (Lilly) for the development of Foundation Medicine’s tissue- and blood-based assays as companion diagnostics for RETEVMO® and other therapies in Loxo Oncology at Lilly’s pipeline. The partnership will initially explore the use of FoundationOne®CDx for adult patients with metastatic rearranged transfection (RET) [...]

Tempus Announces the Acquisition of Highline Sciences

2022-02-10T17:25:39-05:00February 10th, 2022|

Tempus, a leader in artificial intelligence and precision medicine, today announced the acquisition of Highline Sciences, a ​​specialized, full-service clinical contract research organization (CRO) focused on oncology. Highline Sciences manages and executes on early and late-stage clinical trials, applying a customized approach to each study. Highline’s capabilities and expertise will help support and grow [...]

Element Biosciences Closes Acquisition of Loop Genomics

2022-02-10T17:23:41-05:00February 10th, 2022|

Element Biosciences, developer of a new and disruptive DNA sequencing platform, today announced that the company has closed its acquisition of Loop Genomics, a long-read solutions company that enables short-read sequencers to obtain long-range information. Loop Genomics' Chief Executive Officer and Founder, Tuval Ben-Yehezkel, Ph.D., will join Element Biosciences' leadership team as Senior Director, [...]

OneOncology Names Dr. Davey Daniel as Chief Medical Officer

2022-02-10T17:21:44-05:00February 10th, 2022|

OneOncology, the national platform for independent community oncology practices, announced today that Davey Daniel, MD has been appointed Chief Medical Officer succeeding Lee Schwartzberg, MD. Schwartzberg served as the founding member of the platform's clinical office and will remain a senior advisor to the company. Dr. Daniel is currently the Vice Chair of OneCouncil, [...]

Fabric Genomics Appoints Industry Veteran Jyoti Palaniappan as Chief Commercial Officer

2022-02-03T20:01:56-05:00February 3rd, 2022|

Fabric Genomics, Inc., a leader in AI-based clinical decision support platforms for genomics-driven precision medicine, today announced the appointment of Jyoti Palaniappan to its executive leadership team in the role of Chief Commercial Officer. He brings more than 20 years of experience delivering high growth for innovative healthcare companies to Fabric Genomics. “I am [...]

MRM Proteomics, Inc. and Agilent Technologies, Inc.: A Collaboration for Progress

2022-02-03T19:53:47-05:00February 3rd, 2022|

MONTREAL--(BUSINESS WIRE)--MRM Proteomics, Inc. (MRMP) and Agilent Technologies Inc. are excited to announce their new co-marketing agreement aimed to further advance the capabilities of quantitative proteomic applications and thereby help the scientific community make impactful, novel scientific discoveries. “We are impressed with the scanning speed of the Agilent 6495C triple quad MS and the [...]

Illumina partners with centers across France to advance a precision medicine approach for patients with late-stage cancer

2022-02-03T19:49:41-05:00February 3rd, 2022|

Illumina, Inc. (NASDAQ:ILMN), today announced an agreement with the Jean Perrin Center at the Clermont-Ferrand University Hospital in France to assess the clinical value of comprehensive genomic profiling (CGP) in cancer therapy options in patients with late-stage disease compared to use of current standard of care, including small panel tests. Evidence from the CELIA [...]

Novartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021

2022-02-03T19:47:29-05:00February 3rd, 2022|

Basel, February 2, 2022 - commenting on 2021 results, Vas Narasimhan, CEO of Novartis, said: “Novartis delivered another year of solid operational performance with mid-single digit top-line growth, margin expansion, and strong free cash flow. Our in-market growth drivers continue to perform well across geographies, supporting our confidence in our mid and long-term growth [...]

Go to Top